Following Today's Kosan (KOSN) Buyout, Investors Look for Next Biotech Deal
More News related to AFFY
- Affymax (AFFY) Closes Stock Offering, Receiving Net Proceeds of $80M
- Affymax Announces Close of Common Stock Offering and Exercise of Underwriters' Overallotment Option
- Affymax (AFFY) Prices 4.1M Shares at $18.25/Share
- Affymax Prices Public Offering of Common Stock
- After-Hours Movers 11/18: DCI, CYBX, LTD Higher; JACK, NMM, AFFY, HOTT, SMTC, MVIS Lower
More News related to ARQL
- Drug Discovery Capabilities of ArQule Kinase Inhibitor Platform Presented at AACR-NCI-EORTC Conference
- ArQule, Inc. to Present at Lazard Capital Markets Sixth Annual Healthcare Conference on November 17, 2009
- ArQule (ARQL) Posts Q3 Loss of $0.18, Beats Estimates; Reaffirms Guidance
- ArQule Announces Third Quarter Fiscal 2009 Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to BMRN
- BioMarin to Present at the NASDAQ OMX 23rd Investor Program
- BioMarin (BMRN) Responds to News of Contamination at Genzyme (GENZ) Plant; Says Aldurazyme, Naglazyme Won't Be Impacted
- Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
- United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
- BioMarin to Present at the Credit Suisse Healthcare Conference
More News related to Insiders' Blog
- Davenport Upgrades Heinz (HNZ) to Buy
- First Analysis Upgrades Advisory Board Company (ABCO) to Overweight
- Jefferies & Co Upgrades Energy XXI (EXXI) to Hold
- Morgan Stanley Upgrades Iowa Telecom (IWA) to Equalweight
- Fox-Pitt Upgrades Eaton Vance (EV) to Outperform
Following today's buyout of small biotech Kosan Biosciences, Inc. (NASDAQ: KOSN) by Bristol-Myers Squibb (NYSE: BMY) at a 200%+ premium, investors are on the lookout for the next biotech deal.
Today's deal follows other recent biotech takeovers including Millennium Pharmaceuticals (NASDAQ: MLNM), Sirtris Pharmaceuticals (Nasdaq: SIRT), Encysive Pharmaceuticals Inc. (Nasdaq: ENCY), and Restore Medical, Inc. (NASDAQ: REST).
Here are some biotech companies that could be next to be acquired: Onyx Pharmaceuticals (NASDAQ: ONXX), OSI Pharmaceuticals (NASDAQ: OSIP), ImClone (NASDAQ: IMCL), ISIS Pharmaceuticals (NASDAQ: ISIS), BioMarin Pharmaceutical (NASDAQ: BMRN), ArQule (NASDAQ: ARQL), Regeneron (NASDAQ: REGN), Affymax (NASDAQ: AFFY), Medivation (NASDAQ: MDVN).
Related Categories
Insiders' BlogRumors
Stocks Mentioned
+0.14
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
